Compare AIR & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIR | CRNX |
|---|---|---|
| Founded | 1951 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.9B |
| IPO Year | 1994 | 2018 |
| Metric | AIR | CRNX |
|---|---|---|
| Price | $135.28 | $83.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $131.20 | $76.75 |
| AVG Volume (30 Days) | 397.9K | ★ 6.0M |
| Earning Date | 03-24-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.59 | N/A |
| Revenue | N/A | ★ $1,039,000.00 |
| Revenue This Year | $18.83 | $720.10 |
| Revenue Next Year | $10.93 | $184.67 |
| P/E Ratio | $37.27 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $71.43 | $25.83 |
| 52 Week High | $146.75 | $84.00 |
| Indicator | AIR | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 92.91 |
| Support Level | $128.00 | $41.42 |
| Resistance Level | $146.75 | N/A |
| Average True Range (ATR) | 5.19 | 0.85 |
| MACD | -1.36 | 2.82 |
| Stochastic Oscillator | 38.83 | 99.68 |
AAR Corp is engaged in providing products and services to aviation, government and defense market. It operates in segments namely: The parts supply segment majorly consists of sales and leasing of USM and aftermarket distribution of new, OEM-supplied replacement parts; Repair & Engineering segment provides airframe maintenance, component repair, and landing gear overhaul services; Integrated Solutions segment consists of its fleet management and operations of customer-owned aircraft, customized performance-based supply chain logistics programs in support of the U.S. Department of Defense, flight hour component inventory; and The Expeditionary Services segment consists of products and services supporting the movement of equipment and personnel by the U.S. and foreign governments and NGOs.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.